Comparative Pharmacology
Head-to-head clinical analysis: PERCODAN versus TALWIN COMPOUND.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERCODAN versus TALWIN COMPOUND.
PERCODAN vs TALWIN COMPOUND
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia. Oxycodone acts on the central nervous system (CNS) to produce analgesia. Aspirin inhibits cyclooxygenase, leading to decreased prostaglandin synthesis, which reduces pain and inflammation.
TALWIN COMPOUND contains pentazocine, a mixed agonist-antagonist at opioid receptors with partial agonist activity at mu receptors and full agonist activity at kappa receptors, and naloxone, an opioid antagonist that reduces abuse potential by precipitating withdrawal in opioid-dependent individuals when injected. The combination provides analgesia through pentazocine's central and peripheral opioid receptor activation, while naloxone is not absorbed orally but prevents intravenous abuse.
1-2 tablets orally every 4-6 hours as needed for pain. Each tablet contains oxycodone 4.5 mg and aspirin 325 mg.
1-2 tablets (each tablet contains pentazocine HCl 12.5 mg and aspirin 325 mg) orally every 3-4 hours as needed, not to exceed 6 tablets per day.
None Documented
None Documented
Oxycodone: 3-5 hours, prolonged in elderly, hepatic/renal impairment. Aspirin: 2-3 hours at low doses; 15-30 hours at anti-inflammatory doses due to saturable metabolism.
Pentazocine: 2-3 hours; naloxone: 1-1.5 hours. Clinical context: Repeated dosing may prolong effective half-life due to tissue accumulation.
Oxycodone: primarily renal (65-87% as parent and metabolites, mostly noroxycodone and oxymorphone conjugates); ~10% fecal. Aspirin: renal (75-90% as salicylates and metabolites, dose-dependent).
Renal: 60-70% as unchanged drug and metabolites; biliary/fecal: 20-30% as conjugates.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination